Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Sunvozertinib |
Synonyms | |
Therapy Description |
Sunvozertinib (DZD9008) is an irreversible EGFR inhibitor that preferentially inhibits mutant EGFR and ERBB2 (HER2), which may lead to growth inhibition of tumor cells with EGFR activation (AACR Annual Meeting 2019, Abstract 3081, PMID: 35404393). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sunvozertinib | DZD9008|DZD-9008|DZD 9008 | EGFR Inhibitor (Pan) 61 HER2 Inhibitor 41 | Sunvozertinib (DZD9008) is an irreversible EGFR inhibitor that preferentially inhibits mutant EGFR and ERBB2 (HER2), which may lead to growth inhibition of tumor cells with EGFR activation (AACR Annual Meeting 2019, Abstract 3081, PMID: 35404393). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03974022 | Phase Ib/II | Sunvozertinib | Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | Recruiting | USA | ITA | FRA | ESP | AUS | 4 |